Table 1.
Some clinical data of patients at the baseline evaluation. Significance is reported between subjects with (on) L-T4 and without (off) L-T4 therapy for the entire period of TV evaluation. Significance values are: (a) P=0.10, (b) P=0.18, (c) P=0.19, (d) P=0.29, (e) P=0.01 on Mann-Whitney test; (f) P=0.36 on Fisher’s test.
| All (n=94) | On L-T4 (n=48) | Off L-T4 (n=19) | |
|---|---|---|---|
| Age (year); mean ± SD | 49.8 ± 14.5 | 52.5 ± 15.0 | 46.1 ± 11.6 (a) |
| BMI (kg/m2); median, IQR | 23.4; 21.2-26.7 | 24.0; 22.3-27.9 | 23.5; 20.7-26.1 (b) |
| BSA (m2); median, IQR | 1.65; 1.57-1.72 | 1.67; 1.59-1.73 | 1.61; 1.53-1.72 (b) |
| Thyroid volume (mL), median, IQR | 8.3; 5.6-11.1 | 7.1; 5.1-10.1 | 9.1; 6.2-12.3 (c) |
| Former/current smokers (%) | 37 52% | 15/40 (38%) | 8/15 (53%) (f) |
| Non-smokers (%) | 34 48% | 25/40 (62%) | 7/15 (47%) |
| TSH (mIU/L); median, IQR | 3.23; 1.69-6.17 | 2.44; 1.42-4.02 | 1.61; 1.34-3.44 (d) |
| f-T4 (pmol/L); median, IQR | 14.2; 11.7-16.2 | 15.2; 12.4-17.4 | 12.9; 10.4-15.2 (e) |
| L-T4 (µg/kg bw/day); median, IQR | - | 0.98; 0.88-1.43 | n.e |
| Other ongoing drugs; % none |
45% |
42% |
42% |
| hypotensive drugs | 18% | 23% | 16% |
| psychotropic drugs | 18% | 17% | 21% |
| anti-reabsorptive drugs/vitamin D/Ca | 16% | 21% | 21% |
| hormonal contraceptive/HRT | 12% | 13% | 16% |
| anti-secretory drugs | 10% | 8% | 16% |
| statins | 10% | 4% | 10% |
| steroids/NSAIDs | 8% | 10% | 10% |
| H1-inhibitors | 3% | 6% | 0% |
NSAIDs =nonsteroidal anti-inflammatory drugs.